A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Avadel Pharmaceuticals PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 182,900 shares of AVDL stock, worth $2.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
182,900
Previous 151,700 20.57%
Holding current value
$2.61 Million
Previous $2.14 Million 44.21%
% of portfolio
0.0%
Previous 0.0%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$12.55 - $17.22 $11.9 Million - $16.4 Million
950,705 Added 155.04%
1,563,890 $26.4 Million
Q4 2023

Feb 14, 2024

BUY
$9.64 - $14.59 $1.45 Million - $2.19 Million
150,080 Added 32.41%
613,185 $8.66 Million
Q3 2023

Nov 14, 2023

SELL
$10.3 - $15.99 $237,827 - $369,209
-23,090 Reduced 4.75%
463,105 $4.77 Million
Q2 2023

Aug 14, 2023

BUY
$8.48 - $16.48 $1.42 Million - $2.76 Million
167,714 Added 52.66%
486,195 $8.01 Million
Q1 2023

May 15, 2023

BUY
$6.41 - $9.95 $1.4 Million - $2.17 Million
218,484 Added 218.49%
318,481 $2.92 Million
Q4 2022

Feb 14, 2023

BUY
$5.73 - $10.0 $61,179 - $106,770
10,677 Added 11.95%
99,997 $715,000
Q3 2022

Nov 14, 2022

SELL
$2.57 - $7.31 $184,376 - $524,434
-71,742 Reduced 44.54%
89,320 $447,000
Q2 2022

Aug 15, 2022

BUY
$1.07 - $6.95 $79,570 - $516,836
74,365 Added 85.78%
161,062 $393,000
Q1 2022

May 16, 2022

SELL
$5.46 - $8.29 $189,347 - $287,488
-34,679 Reduced 28.57%
86,697 $592,000
Q4 2021

Feb 14, 2022

BUY
$7.34 - $11.18 $239,203 - $364,345
32,589 Added 36.7%
121,376 $980,000
Q3 2021

Nov 15, 2021

SELL
$6.49 - $9.91 $165,637 - $252,923
-25,522 Reduced 22.33%
88,787 $870,000
Q2 2021

Aug 16, 2021

BUY
$6.73 - $9.05 $7,685 - $10,335
1,142 Added 1.01%
114,309 $769,000
Q1 2021

May 17, 2021

BUY
$6.61 - $10.07 $161,654 - $246,271
24,456 Added 27.57%
113,167 $1.02 Million
Q4 2020

Feb 16, 2021

BUY
$5.03 - $7.95 $84,458 - $133,488
16,791 Added 23.35%
88,711 $593,000
Q3 2020

Nov 16, 2020

BUY
$5.02 - $8.98 $110,173 - $197,084
21,947 Added 43.92%
71,920 $363,000
Q2 2020

Aug 14, 2020

BUY
$7.25 - $11.75 $223,002 - $361,418
30,759 Added 160.09%
49,973 $404,000
Q1 2020

May 15, 2020

SELL
$4.06 - $10.64 $479,664 - $1.26 Million
-118,144 Reduced 86.01%
19,214 $153,000
Q4 2019

Feb 14, 2020

BUY
$3.34 - $7.7 $372,149 - $857,949
111,422 Added 429.6%
137,358 $1.04 Million
Q3 2019

Nov 14, 2019

SELL
$1.92 - $4.47 $12,224 - $28,460
-6,367 Reduced 19.71%
25,936 $107,000
Q2 2019

Aug 14, 2019

SELL
$1.09 - $3.19 $70,394 - $206,016
-64,582 Reduced 66.66%
32,303 $93,000
Q4 2018

Feb 14, 2019

SELL
$1.74 - $4.66 $42,551 - $113,960
-24,455 Reduced 20.15%
96,885 $249,000
Q3 2018

Nov 13, 2018

SELL
$4.08 - $7.14 $525,304 - $919,282
-128,751 Reduced 51.48%
121,340 $0
Q2 2018

Aug 10, 2018

BUY
$5.89 - $7.78 $761,812 - $1.01 Million
129,340 Added 107.11%
250,091 $0
Q1 2018

May 11, 2018

SELL
$6.76 - $11.7 $188,766 - $326,710
-27,924 Reduced 18.78%
120,751 $880,000
Q4 2017

Feb 09, 2018

BUY
$8.03 - $11.25 $430,456 - $603,067
53,606 Added 56.39%
148,675 $1.22 Million
Q3 2017

Nov 09, 2017

BUY
$8.35 - $10.5 $793,826 - $998,224
95,069
95,069 $998,000

Others Institutions Holding AVDL

About AVADEL PHARMACEUTICALS PLC


  • Ticker AVDL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 60,581,300
  • Market Cap $866M
  • Description
  • Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...
More about AVDL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.